JON E ARNASON

Allopathic & Osteopathic Physicians|Internal Medicine NEW YORK, NY NPI 1376701136

General Payments — all program years on this page

$28,265.73

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 27
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $19,136.99 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Travel and Lodging $10,966.9912
Consulting Fee $8,170.005

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Regeneron Pharmaceuticals, Inc. $19,136.9917

By program year

Program yearAmountRecords
2018 $4,202.234
2019 $145.522
2021 $3,690.001
2023 $1,090.993
2024 $19,136.9917

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1114396124 Regeneron Pharmaceuticals, Inc. $9,539.10 03/19/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396126 Regeneron Pharmaceuticals, Inc. $25.25 03/19/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396128 Regeneron Pharmaceuticals, Inc. $817.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396130 Regeneron Pharmaceuticals, Inc. $4,085.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396132 Regeneron Pharmaceuticals, Inc. $817.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396134 Regeneron Pharmaceuticals, Inc. $817.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396136 Regeneron Pharmaceuticals, Inc. $1,634.00 10/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396138 Regeneron Pharmaceuticals, Inc. $425.65 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396140 Regeneron Pharmaceuticals, Inc. $20.51 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396142 Regeneron Pharmaceuticals, Inc. $15.17 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396144 Regeneron Pharmaceuticals, Inc. $26.95 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396146 Regeneron Pharmaceuticals, Inc. $15.71 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396148 Regeneron Pharmaceuticals, Inc. $21.52 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396150 Regeneron Pharmaceuticals, Inc. $23.65 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396152 Regeneron Pharmaceuticals, Inc. $2.17 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396154 Regeneron Pharmaceuticals, Inc. $425.65 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396156 Regeneron Pharmaceuticals, Inc. $425.66 10/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.